AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16108771
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of Peginterferon alpha‐2b administered twice weekly + ribavirin (Group B)
Trial: 6239753
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg meptazinol 4-times daily for up to 3 weeks
Trial: 6239753
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg diflunisal 4-times daily for up to 3 weeks
Trial: 31021886
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg intravenous dexamethasone before incision
Trial: 31021886
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral pregabalin 1 hour before surgery
Trial: 31021886
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.2 mg/kg intravenous dexamethasone and 150 mg oral pregabalin
Trial: 27568165
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education program (n=817) consisting of weekly to monthly workshops covering relevant health information
Trial: 9274835
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil (MMF) in conjunction with ciclosporin and steroids
Trial: 9274835
Drug: Ciclosporin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin and steroids
Trial: 24886488
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily in addition to routine care
Trial: 23570952
Drug: Various antidepressants
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antidepressants and augmentation strategies including extended-release venlafaxine, mitazapine, paroxetine, risperidone, sodium valproate, buspirone, trazodone, thyroid hormone augmenting to paroxetine
Trial: 17121727
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine combined with fentanyl (KF group)
Trial: 10223773
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once a day for 5 days
Trial: 6806060
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cimetidine in the evening (group A)
Trial: 6806060
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cimetidine both morning and evening (group B)
Trial: 30523032
Drug: Roux-en-Y gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux-en-Y gastric bypass (RYGB) with exendin(9-39) infusion
Trial: 21390540
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention (Project EXPLORE), details on dosage and duration not specified.
Trial: 7049307
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg on the day of operation and for the following 2 days)
Trial: 31487406
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg (T100)
Trial: 31487406
Drug: Tildrakizumab 200
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab 200 mg (T200)
Trial: 31487406
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg (T100) with placebo (PBO)
Trial: 31487406
Drug: Tildrakizumab 200
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab 200 mg (T200) with placebo (PBO)
Trial: 31487406
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) switching to Tildrakizumab 200 mg (ETN/T200)
Trial: 24122669
Drug: Artemether-lumefantrine (A-L)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (A-L)
Trial: 21615951
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving therapy, regular written communication, patient support, cultural assessment, improved access to primary care, risk management strategy
Trial: 21615951
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (treatment as usual)
Trial: 18305265
Drug: Low-dose vasopressin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vasopressin (0.01 to 0.03 U per minute)
Trial: 18305265
Drug: Low-dose vasopressin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vasopressin (0.01 to 0.03 U per minute) in less severe septic shock
Trial: 18305265
Drug: Low-dose vasopressin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vasopressin (0.01 to 0.03 U per minute) in more severe septic shock
Trial: 15945499
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (appropriate medications)
Trial: 8578059
Drug: Gabapentin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (900 to 1800 mg/day)
Trial: 2054316
Drug: Epirubicin 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 120 mg/m2 i.v. push every 21 days pre-operatively, and four additional courses post-operatively (group I)
Trial: 2054316
Drug: Histopathological study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histopathological study of resected specimens after initial chemotherapy
Trial: 24892115
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene procedures (1 hour session)
Trial: 19571597
Drug: sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline plus atomoxetine
Trial: 17890427
Drug: Rosiglitazone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone therapy for 12 weeks
Trial: 15375799
Drug: glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide (5 mg/d)
Trial: 15375799
Drug: voglibose (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: voglibose (0.6 mg/d)
Trial: 27143662
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitor monotherapy (PI-monotherapy)
Trial: 27143662
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination ART (OT group)
Trial: 18782697
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia alone
Trial: 16640102
Drug: Atazanavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir (300 mg once daily) boosted by Ritonavir (100 mg) for 2 weeks, followed by ATV, RTV, and TDF-DF (300 mg) plus optimized NRTIs regimen.
Trial: 10949980
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1 g cefodizime
Trial: 10949980
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 1 g cefodizime
Trial: 10949980
Drug: Skin suction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin suction blister fluid (SBF) after cefodizime administration
Trial: 7935568
Drug: Fluconazole, 200
RxNorm normalized name: Fluconazole, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 200 mg once a day
Trial: 7935568
Drug: Oral amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amphotericin B, 800 mg three times a day
Trial: 3741534
Drug: Metronidazole, 500
RxNorm normalized name: MetroNIDAZOLE, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole, 500 mg i.v.
Trial: 3741534
Drug: Latamoxef (lamoxactam),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latamoxef (lamoxactam), 2 g i.v.
Trial: 17477110
Drug: Drospirenone in
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drospirenone in combination with 17β‐estradiol
Trial: 15110210
Drug: Sequential acquisition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential acquisition protocol
Trial: 11812391
Drug: Fluid ingestion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid ingestion (H1 and E1) - solution containing 50 g l(‐1) glucose and 1.34 g l(‐1) NaCl in a volume of water corresponding to 100% of body weight loss
Trial: 11812391
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (H0, E0) - solution containing the same quantity of glucose diluted in 100 ml of water
Trial: 319116
Drug: Indomethacin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (80 mg/day)
Trial: 30735919
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus metronomic chemotherapy (capecitabine 500 mg three times per day and cyclophosphamide 50 mg/die)
Trial: 30735919
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus metronomic chemotherapy (capecitabine and cyclophosphamide)
Trial: 22404081
Drug: Functionally orientated
RxNorm normalized name: Papaver orientale seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functionally orientated treatment using resin-bonded bridgework (RBB) to restore to a Shortened Dental Arch (SDA) of 10 occluding contacts
Trial: 22001281
Drug: Separate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate vaccines (DTaP, IPV, PRP∼T) booster
Trial: 19858155
Drug: Pramlintide (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (maximum dose: 30 microg per meal)
Trial: 16622259
Drug: docetaxel 43
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 43 mg/m2 weekly alone (cohort A)
Trial: 16622259
Drug: docetaxel 43
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 43 mg/m2 weekly plus etanercept 25 mg subcutaneously twice weekly (cohort B)
Trial: 16622259
Drug: docetaxel 52
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 52 mg/m2 weekly with etanercept
Trial: 15642958
Drug: Dihydroartemisinin formulations
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin formulations (Cotecxin, Arenco n.v. Pharmaceutica, Mahidol University)
Trial: 15642958
Drug: Dihydroartemisinin formulations
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin formulations
Trial: 9849452
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus chemotherapy (carboplatin 300 mg/m2 on day 1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eight courses)
Trial: 3047337
Drug: Chemotherapy (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (exact regimen not specified)
Trial: 7812703
Drug: Half doses
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half doses of drugs at the first cycle (suggested intervention)
Trial: 31729127
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide
Trial: 31729127
Drug: Sulphonylurea gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea gliclazide plus other glucose-lowering drugs targeting a glycated hemoglobin value of 6.5% or less
Trial: 25675123
Drug: Erlotinib (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (once daily)
Trial: 25675123
Drug: Chemotherapy (3-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (3-weekly cycles)
Trial: 23241734
Drug: Nefopam-Paracetamol combination
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam-Paracetamol combination
Trial: 23241734
Drug: Nefopam and
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam and Paracetamol combination
Trial: 19040340
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs and new approaches including response prediction based on sequential (18)FDG‐PET scanning following induction chemotherapy
Trial: 8057515
Drug: Maximized glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximized glycemic control (subcutaneous insulin given several times a day or continuously)
Trial: 8057515
Drug: Standard glycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycemic control (subcutaneous insulin given once or twice each day)
Trial: 8057515
Drug: Maximized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximized treatment
Trial: 3140744
Drug: L-arginine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (25 g/day, n = 16)
Trial: 3140744
Drug: L-glycine (43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glycine (43 g/day, n = 14)
Trial: 31513665
Drug: Anakinra (IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (IL-1 inhibitor)
Trial: 31513665
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab, golimumab)
Trial: 29021371
Drug: Double-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-fortified salt (DFS) containing 47 mg potassium iodate/kg and 3.3 mg microencapsulated ferrous fumarate/g (1.1 mg elemental Fe/g)
Trial: 22912456
Drug: Dietary choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary choline supplementation at 2,960 mg/kg
Trial: 22912456
Drug: Dietary choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary choline supplementation at 370 mg/kg
Trial: 19330795
Drug: Venlafaxine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine SR (75-150 mg/die)
Trial: 19330795
Drug: Fluoxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-40 mg/die)
Trial: 17848609
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml wine (13 g alcohol) daily for 3 months
Trial: 17848609
Drug: Nonalcoholic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonalcoholic diet beer (control) daily for 3 months
Trial: 11780926
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BMS-193884
Trial: 15512224
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin combined with fish oil
Trial: 15512224
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin only
Trial: 15512224
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin combined with evening primrose oil
Trial: 7884952
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg TNF‐alpha MAb
Trial: 7884952
Drug: 7.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg TNF‐alpha MAb
Trial: 2229305
Drug: Pyridostigmine (PD)
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD) 120 mg oral
Trial: 651762
Drug: Reptilase (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reptilase (1 ml)
Trial: 31862699
Drug: Oxandrolone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.05 mg/kg/day (maximum dose 2.5 mg)
Trial: 31150800
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.75% ropivacaine
Trial: 31150800
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of 0.75% ropivacaine
Trial: 31150800
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.75% ropivacaine
Trial: 31150800
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml and 15 ml of 0.75% ropivacaine
Trial: 28321637
Drug: Concentric-only resistance
RxNorm normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentric-only resistance training (dumbbell curls and shoulder presses, twice per week for 4 weeks)
Trial: 17576783
Drug: Sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10 mg daily)
Trial: 9702848
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics (bumetanide 1 mg daily and furosemide 40 mg daily)
Trial: 9702848
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg daily
Trial: 9606629
Drug: Dithranol (D)
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dithranol (D) twice a day (D/D)
Trial: 30633218
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2g on both shoulders)
Trial: 30633218
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point injection (2mL of 0.2% ropivacaine)
Trial: 27089170
Drug: lenalidomide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6
Trial: 25006768
Drug: Socket grafting,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socket grafting, buccal overbuilding, and PTFE barrier
Trial: 20398311
Drug: EcN 40
RxNorm normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN 40 ml enema (10E8 EcN/ml)
Trial: 20398311
Drug: EcN 20
RxNorm normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN 20 ml enema (10E8 EcN/ml)
Trial: 20398311
Drug: EcN 10
RxNorm normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN 10 ml enema (10E8 EcN/ml)
Trial: 18507881
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with vitamins/minerals (Pharmaton Kiddi) for 12 weeks
Trial: 14581796
Drug: Low-dose erythromycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose erythromycin (5 mg/kg every 8 hours)
Trial: 14581796
Drug: Low-dose erythromycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose erythromycin
Trial: 10654172
Drug: Early grid
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early grid laser treatment
Trial: 10654172
Drug: Delayed grid
RxNorm normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed grid laser treatment
Trial: 8241496
Drug: All transretinoic
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All transretinoic acid (ATRA) combined with daunorubicin‐Ara C chemotherapy
Trial: 8241496
Drug: Daunorubicin‐Ara C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin‐Ara C chemotherapy
Trial: 31035469
Drug: Aquilea Colesterol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquilea Colesterol® (nutraceutical combination)
Trial: 30284506
Drug: Both rTMS
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both rTMS and constraint therapy